Skip to content

fMRI in Blood Phobia Syncope

Neuroimaging in Blood Phobia Syncope

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00715065
Enrollment
0
Registered
2008-07-15
Start date
2010-06-30
Completion date
2010-06-30
Last updated
2013-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Syncope, Blood Injury Phobia, Autonomic Dysfunction

Keywords

syncope, faint, blood, blood injury phobia, phobia

Brief summary

We plan to study patient who faint in response to the sight of blood and compare them to healthy subjects who do not. We are going to use a special type of MRI scan (functional MRI) to determine if there are differences in brain activation in response to seeing bloody or gory pictures that occur before the fainting occurs.

Detailed description

Another aim of the study is to determine whether or not differences in personality traits among people with blood phobia is associated with differences in BOLD signal responses during fMRI.

Interventions

PROCEDUREfMRI Scan

Subjects will undergo a functional MRI scan of the head lasting \ 45 minutes. They will be repeatedly shown video clips of blood, other disgusting things, or are neutral.

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
Vanderbilt University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-30 years of age * 1\. History of at least one syncopal episode upon exposure to viewing blood (Case Group) * Negative urine pregnancy test on study day

Exclusion criteria

* Vasoactive medications (within 2 weeks of study day) * antihypertensives * beta blockers * vasoconstrictors * Psychotropic medications (within 4 weeks of study day) * History of psychostimulant or opiate use * History of alcohol, benzodiazepine or cannabis abuse or dependence

Design outcomes

Primary

MeasureTime frame
fMRI BOLD signalImmediate

Secondary

MeasureTime frame
Blood Injection Symptoms ScaleSingle visit
Disgust Scale (Revised)Single Visit

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026